2026-06-14T11:55:09Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/201122024-11-28T20:14:20Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967

00925njm 22002777a 4500 dc Gutierrez, Antonio author Bento, Leyre author Maria Bautista-Gili, Antonia author Garcia, Francesc author Martinez-Serra, Jordi author Sanchez, Blanca author Martorell, Clara author Gines, Jordi author Garcia, Lucia author Gimeno, Eva author Ferraro, Mariana author del Campo Garcia, Raquel author Bargay Lleonart, Joan author Perez, Albert author Vercher, Javier author Scaff, Miguel author Pacheco, Ana author Ballester Ruiz, Maria del Carmen author Garcia, Florencia author Ramos-Asensio, Rafael author Salar, Antonio author Besalduch Vidal, Juan author 2015-04-24 DLBCL is an aggressive lymphoma treated with R-CHOP. Recently, attempts have been made to improve the outcome by increasing both dose-density and intensity but there have been no benefits in terms of survival. When treating malignancies RDI is important to consider but there is little published information on DLBCL. The purpose of this study was to analyze the differential prognostic impact of RDI in two cohorts of DLBCL patients treated with R-CHOP21 or R-CHOP14. From January 2001 to August 2013 we included DLBCL patients homogenously treated with R-CHOP21 or R-CHOP14, with or without radiotherapy, at University Hospital Son Espases, Hospital Son Llatzer of Palma and Hospital del Mar of Barcelona (N = 157). In order to avoid selection bias the patients were retrospectively identified from the Pathology Department and Pharmacy registries. Median follow-up was 68 months. There was no difference in the response or survival between the two cohorts. In the R-CHOP21 group, both a reduction higher than 15% in RDI (RR 7.41) and R-IPI (RR 2.99) were independently associated with OS. However, a reduction higher than 15% in RDI (RR 4.41) was only noted for PFS. In the R-CHOP14 group, NCCN-IPI (RR 7.09) and B-symptoms (RR 5.37) for OS; AA stage III-IV (RR 6.26) and bulky disease (RR 4.05) for PFS. There was a trend towards a higher rate of RDI reduction observed in the R-CHOP14 group but it only made an impact in the R-CHOP21 group. We conclude that R-CHOP21 and R-CHOP14 are equivalent regimens in terms of response and survival, but only if RDI reductions are avoided. For patients receiving R-CHOP21 we recommend using clinical and support measures in order to avoid RDI reductions. Gutierrez A, Bento L, Bautista-Gili AM, Garcia F, Martinez Serra JJ, Sanchez B, et al. Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14. PLoS One. 2015 Apr 24;10(4):e0123978. 10.1371/journal.pone.0123978 1932-6203 PloS One http://hdl.handle.net/20.500.13003/10877 25909361 L604108257 2-s2.0-84929483958 http://hdl.handle.net/20.500.12105/20112 353376800053 Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14